News | Point of Care Testing | December 22, 2015

Trinity Biotech Submits High Sensitivity Troponin I Product to FDA

Assay and analyzer work together to diagnose myocardial infarction in the emergency department within 15 minutes

December 22, 2015 — Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI) point-of-care assay for U.S. Food and Drug Administration (FDA) 510(k) clearance. The company is seeking clearance for both systems for use in the diagnosis of myocardial infarction (MI).

The cTnI assay will enable healthcare professionals to quickly determine patient cardiac status in emergency department settings, to accelerate patient care and to reduce overall costs of delivering health care.

The Meritas cTnI assay is run on the Meritas Point of Care Analyzer. The single-use, pre-calibrated cTnI assay is simple to use, and delivers cTnI results in about 15 minutes in both whole blood and plasma samples. The assay combines sensitive antibody reagents and the use of advanced injection molding technologies to create high-fidelity micropillar structures to control sample fluidics. Clinical data was collected at 14 geographically dispersed locations across the United States, and MIs were determined by a panel of independent adjudicators. 

Clinical performance results of the product at the time of admission to the hospital emergency room demonstrated 66 percent sensitivity and 84 percent specificity for whole blood; results were 78 percent and 95 percent, respectively, for plasma.

For more information: www.trinitybiotech.com

Related Content

Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
Overlay Init